by | Jun 24, 2024 | Uncategorized
Source: ASCO Daily News Drs. John Sweetenham and Marc Braunstein discuss practice-changing studies in hematologic malignancies that were featured at the 2024 ASCO Annual Meeting, including the ASC4FIRST trial in chronic myeloid leukemia and IMROZ and CARTITUDE-4 in...
by | Jun 20, 2024 | Uncategorized
Source: CureToday articles During the CURE® Educated Patient® Multiple Myeloma Summit, one expert explained the push to make CAR-T cell therapy available for patients sooner. Read More
by | Jun 19, 2024 | Uncategorized
Source: CureToday articles One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma. Read More
by | Jun 19, 2024 | Uncategorized
Source: CureToday articles One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma. Read More
by | Jun 19, 2024 | Uncategorized
Source: CureToday articles One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma. Read More
by | Jun 19, 2024 | Uncategorized
Source: CureToday articles One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma. Read More
